Sidekick and Pfizer Launch Digital Therapeutic Solutions for Atopic Dermatitis

The digital therapeutic firm, Sidekick Health, has teamed up with giant Pfizer to launch an integrated digital therapeutic solution for Atopic Dermatitis (AD).

The solution will first be launched in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland and Japan later this year.

This marks a later stage Growing collaboration between Sidekick and Pfizer Develop a global digital patient support program with expansion to 24 markets by 2024.

Why it matters

AD is an inflammatory, pruritic, chronic or chronic relapsing skin disease that affects up to 14% of adults worldwide. People living with moderate to severe AD often suffer from constant and relentless itching, which leads to lack of sleep, increased stress and anxiety which affects their quality of life.

However, one of the challenges of effectively treating AD is that patients have low adherence to the treatment. Sidekick’s Digital Therapeutics platform aims to provide treatment through care pathways using gamification principles and behavioral economics that help inspire lasting behavioral change. It positively affects health outcomes by addressing the same endpoints as traditional treatments.

Sidekick recently completed an independently funded feasibility study for AD, which showed an increase of more than 40% in the severity of skin lesions, as assessed by dermatologists, and reduced the overall severity of symptoms by about 50%.

People participating in the study also reported significant improvements in health-related quality of life and increased adherence to treatment and preventive measures.

Greater context

Earlier this month, Sidekick announced a shutdown $ 55 million (€ 52M) Series B round That brought its total to $ 75 million (€ 70.8M) in less than two years.

In addition to partnering with Pfizer, the firm has previously worked with pharma firms worldwide BuyerTo develop integrated combination therapeutic.

On the record

Dr. Trigvi Thorgerson, CEO and co-founder, Sidekick, said: “We are excited to enter the next phase of our ongoing relationship with Pfizer. At Sidekick, our ambition was to help people make as much as possible of long-term improvement in their disease management, with the goal of improving their health outcomes and quality of life. Our work with Pfizer further enhances our goal of bringing digital therapeutic to people’s homes around the world. “

Anna Pella Carvalho, Regional President, International Advanced Market, Inflammation and Immunology, Pfizer, said: “Autoimmune and chronic inflammatory diseases, such as atopic dermatitis, can be debilitating, debilitating and debilitating, dramatically affecting what people living with the disease can do.

“At Pfizer, we acknowledge that patient care is beyond medical progress and we are proud to work with Sidekick to make their technology available to those who need it most. An holistic approach to treating individuals is essential, not just to improving the quality of care of patients and empowering them to lead a better life. “

Leave a Reply

Your email address will not be published.